Does Semaglutide or Tirzepatide Cause Muscle Loss?

"Ozempic face" and "muscle loss" both entered the conversation around GLP-1 medications around the same time, and both point at a real phenomenon that gets exaggerated in either direction online. Here is what body-composition research on these drugs actually measures.

Yes, some of the weight lost is lean mass — this is true of weight loss generally

A dedicated review of body-composition changes on GLP-1-based therapies found that a meaningful share of total weight lost — commonly cited in the roughly 25–40% range across studies, versus roughly 20–30% in typical diet-only weight loss — comes from fat-free (lean) mass rather than fat mass alone, and outlined mitigation strategies clinicians can use¹. A separate systematic review and network meta-analysis of GLP-1 receptor agonists and co-agonists on body composition reached a similar picture: significant reductions in fat mass are accompanied by a smaller but real reduction in lean mass across the drug class². Neither paper found this to be unique to GLP-1s — losing some lean mass alongside fat is a near-universal feature of significant weight loss by any method, including bariatric surgery and calorie restriction; the question worth asking is whether it's proportionally worse on a GLP-1, and the honest answer from this data is: modestly higher than diet alone, not dramatically so.

What's actually driving research into mitigation

Because lean mass includes skeletal muscle — and skeletal muscle is metabolically active tissue tied to strength, mobility and long-term metabolic health — losing more of it than necessary is a real concern worth managing, not dismissing. That's exactly why mitigation is an active research area: one line of investigation is pairing GLP-1 therapy with agents like activin type II receptor blockade, which in early research preserved skeletal muscle mass while enhancing fat loss during GLP-1 receptor agonism in animal models³ — an experimental combination approach, not something available in an approved product today, and not a substitute for the two interventions that already have solid evidence behind them.

What actually helps, today

The mitigation strategies with real evidence behind them right now are not exotic: adequate protein intake and resistance (strength) training during GLP-1 treatment. Both directly target the same mechanism — preserving the stimulus and raw material muscle needs to be maintained even in a calorie deficit — and both are explicitly the intervention pathway the lean-mass review above outlines rather than a future drug¹. If you are losing weight quickly on a GLP-1, that is precisely the window where skipping resistance training or protein intake costs you the most lean mass, not the window where it matters least.

What this means for your decision

Muscle loss on a GLP-1 is real but not a reason to avoid the medication category outright — it is a reason to treat the medication as one part of a plan that also includes strength training and adequate protein, the same way you'd approach any significant, sustained weight loss. It is also not evidence that one molecule is meaningfully worse than the other for this specific effect; the class-level pattern in the research above spans both semaglutide and tirzepatide. If you're also weighing the GI side-effect profile of either molecule, see tirzepatide side effects and semaglutide side effects; if cost is what's driving how fast you're titrating or whether you'll sustain treatment long enough to need a mitigation plan, our true monthly cost guide covers the total-cost side of that decision. Not medical advice — talk to a clinician about a resistance-training and protein plan suited to you; see our medical disclaimer.